Page 18 - Anticoagulation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Anticoagulation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Anticoagulation Today - Breaking & Trending Today

Full-Dose Antithrombotic Aids Selected COVID-19 ICU Patients

Compared with reduced-dose prophylaxis, full-dose anticoagulation cut thrombotic events but also boosted bleeding in patients with COVID-19 who needed ICU admission. ....

United States , Comunidad Autonoma De Cataluna , Daiichi Sankyo , Davidd Berg , Johnw Eikelboom , Eduardo Ramacciotti , American Society Of Hematology , Mcmaster University , European Society Of Cardiology , Santa Casa School Of Medicine , American Society , European Society , Santa Casa School , Increased Win Ratio With Full , New England Journal , Mobility Bio , Youngene Therapeutics , 019 Novel Coronavirus , 019 Ncov , Uhan Coronavirus , Uman Coronavirus Hku1 , Uman Coronavirus Oc43 , Cov Oc43 , Uman Coronavirus 229e , Cov 229e , Deep Venous Thrombosis Dvt ,

"Educational Needs of People Living with Atrial Fibrillation: A Qualita" by Caleb Ferguson, Louise D. Hickman et al.

Background This study explored the educational and self-management needs of adults living with atrial fibrillation (AF). Methods and Results This is a qualitative study of adults living with AF, clinicians, and expert key stakeholders. Interviews were conducted via a one-to-one semistructured videoconference or phone and transcribed verbatim for thematic analysis. A total of 34 participants were recruited and included in analyses (clinicians n=13; experts n=13, patients n=8). Interviews were on average 40 (range 20-70) minutes in duration. Three key themes were identified: (1) "Patient-centered AF education"; (2) "Prioritizing AF education"; and (3) "Timing AF education." The availability of credible information was perceived as highly variable. Information primarily focused on anticoagulation, or procedural information, as opposed to other aspects of management, such as risk factor reduction. Factors to optimize learning, such as multimedia, apps, case st ....

Results This , Atrial Fibrillation , Patient Education , Self Management ,

Two Old Meds and a DOAC a Bust in COVID-19: The ACT Trials

It s the end of the story for colchicine in COVID-19, an expert said. In addition, aspirin does not help outpatients with COVID and a low-dose oral anticoagulant does not improve inpatient outcomes. ....

United States , Comunidad Autonoma De Cataluna , David Berg , John Eikelboom , Sanjit Jolly , European Society Of Cardiology Congress , Mcmaster University , Maastricht University , Population Health Research Institute , Anti Coronavirus Therapy , European Society , Cardiology Congress , Arteriovenous Thrombotic Events , Critically Ill , 019 Novel Coronavirus , 019 Ncov , Uhan Coronavirus , Uman Coronavirus Hku1 , Uman Coronavirus Oc43 , Cov Oc43 , Uman Coronavirus 229e , Cov 229e , Factor Xa Inhibitors , Anti Inflammatory Agents , Anticoagulation Therapy , Mechanical Ventilation ,

Factor XIa Inhibitor Encouraging in Phase 2 MI, Stroke Studies

It s all exploratory, but asundexian given with antiplatelets showed safe nuanced potential against poststroke recurrent events and quashed circulating factor XIa after stenting for acute MI. ....

United States , Boston University , North Carolina , United Kingdom , Comunidad Autonoma De Cataluna , Ashkan Shoamanesh , Artivion Cryolife , Bristol Myers Squibb , Mcmaster University , Boehringer Ingelheim , Boston University School Of Medicine , Duke Clinical Research Institute , University Of Liverpool , European Society Of Cardiology , Janssen Pharmaceuticals , European Society , Medscape Cardiology , Boston University School , Anthos Therapeutics , Hot Line Session , Anticoagulation Therapy , Antiplatelet Agent , Myocardial Infarction , Embolic Stroke , Anti Thrombotics , Antithrombotic Therapy ,

AXIOMATIC-SSP: Cautious Optimism on Factor XI Inhibitor in Stroke

The new factor XI inhibitor antithrombotic, milvexian, showed promising results in a dose-finding phase 2 trial in patients with acute ischemic stroke or TIA, on top of dual antiplatelet therapy. ....

Comunidad Autonoma De Cataluna , Giovanna Liuzzo , Mukul Sharma , Mcmaster University , Academic Research Consortium , Catholic University Of Rome , European Society Of Cardiology , European Society , Bleeding Academic Research Consortium , Catholic University , Erebrovascular Accident , Va Cerebrovascular Accident , Ischemic Stroke , Transient Ischemic Attack , Anti Thrombotics , Antithrombotic Therapy , Antithrombotic Agents , Intracerebral Hemmorhage , Traumatic Brain Injury , Bi Traumatic Brain Injury , Anticoagulation Therapy , Recurrent Stroke ,